×
验证码:
换一张
Forgotten Password?
Stay signed in
Login With UMPASS
English
|
繁體
Login With UMPASS
Log In
ALL
ORCID
TI
AU
PY
SU
KW
TY
JN
DA
IN
PB
FP
ST
SM
Study Hall
Image search
Paste the image URL
Home
Faculties & Institutes
Scholars
Publications
Subjects
Statistics
News
Search in the results
Faculties & Institutes
Faculty of Healt... [7]
Institute of Chi... [3]
THE STATE KEY LA... [3]
Authors
HU YUANJIA [2]
LUO QIAN [1]
ZHENG WENHUA [1]
KWOK HANG FAI [1]
OUYANG DEFANG [1]
Document Type
Journal article [6]
Review article [2]
Book chapter [1]
Date Issued
2024 [1]
2023 [1]
2022 [1]
2021 [1]
2017 [4]
2015 [1]
More...
Language
英語English [8]
Source Publication
Cancer [2]
Trends in Cancer [2]
Bioengineering-B... [1]
Current Topics i... [1]
INTERNATIONAL JO... [1]
Oncotarget [1]
More...
Indexed By
SCIE [6]
Funding Organization
Funding Project
×
Knowledge Map
UM
Start a Submission
Submissions
Unclaimed
Claimed
Attach Fulltext
Bookmarks
Browse/Search Results:
1-9 of 9
Help
Selected(
0
)
Clear
Items/Page:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
Sort:
Select
Journal Impact Factor Ascending
Journal Impact Factor Descending
Title Ascending
Title Descending
Author Ascending
Author Descending
Issue Date Ascending
Issue Date Descending
WOS Cited Times Ascending
WOS Cited Times Descending
Submit date Ascending
Submit date Descending
Characteristics of clinical trials of new oncology drugs approved in China
Journal article
Yang, Jing, Yang, Ji, Hu, Yuan Jia. Characteristics of clinical trials of new oncology drugs approved in China[J]. Cancer, 2024, 130(5), 671-682.
Authors:
Yang, Jing
;
Yang, Ji
;
Hu, Yuan Jia
Favorite
|
TC[WOS]:
1
TC[Scopus]:
2
IF:
6.1
/
6.7
|
Submit date:2024/05/16
Clinical Evidence
Drug Lag
Novel Anticancer Drugs
Pivotal Clinical Trials
Programmed Death-1 (Pd-1) Inhibitors
Programmed Death-ligand 1 (Pd-l1) Inhibitors
Characteristics of clinical trials of new oncology drugs approved in China
Review article
2023
Authors:
Jing Yang
;
Ji Yang
;
HU YUANJIA
Adobe PDF
|
Favorite
|
TC[WOS]:
1
TC[Scopus]:
2
IF:
6.1
/
6.7
|
Submit date:2024/01/02
Clinical Evidence
Drug Lag
Novel Anticancer Drugs
Pivotal Clinical Trials
Programmed Death-1 (Pd-1) Inhibitors
Programmed Death-ligand 1 (Pd-l1) Inhibitors
Synthesis of Carrier-Free Paclitaxel–Curcumin Nanoparticles: The Role of Curcuminoids
Journal article
Sena Karaosmanoglu, Yunsen Zhang, Wenli Zhou, Defang Ouyang, Xianfeng Chen. Synthesis of Carrier-Free Paclitaxel–Curcumin Nanoparticles: The Role of Curcuminoids[J]. Bioengineering-Basel, 2022, 9(12), 815.
Authors:
Sena Karaosmanoglu
;
Yunsen Zhang
;
Wenli Zhou
;
Defang Ouyang
;
Xianfeng Chen
Favorite
|
TC[WOS]:
2
TC[Scopus]:
3
|
Submit date:2023/01/30
Hydrophobic Anticancer Drugs
Curcumin
Paclitaxel
Carrier-free Nanoparticles
Self-assembly
Molecular Modeling
Review and prospect of tissue-agnostic targeted strategies in anticancer therapies
Review article
2021
Authors:
Yu Peng
;
Hongxun Tao
;
Yuanqing Gao
;
Yuanyuan Yang
;
Zhiyong Chen
Favorite
|
TC[WOS]:
6
TC[Scopus]:
5
IF:
2.9
/
3.1
|
Submit date:2022/05/13
Anticancer Therapy
Broad-spectrum Anticancer Targeted Drugs
Cancers
Chemotherapy
Precision Medicine
Tissue-agnostic Targeted Therapy
Venom Peptides: Improving Specificity in Cancer Therapy
Journal article
Mahadevappa, Ravikiran, Ma, Rui, Kwok, Hang Fai. Venom Peptides: Improving Specificity in Cancer Therapy[J]. Trends in Cancer, 2017, 3(9), 611-614.
Authors:
Mahadevappa, Ravikiran
;
Ma, Rui
;
Kwok, Hang Fai
Favorite
|
TC[WOS]:
31
TC[Scopus]:
33
|
Submit date:2022/08/01
Combinatorial Anticancer Drugs
Immunotherapy
Targeted Cancer Therapy
Venom Peptides
Venom peptides -- Improving specificity for cancer therapy
Journal article
Mahadevappa, R., Ma, R., Kwok, H. F.. Venom peptides -- Improving specificity for cancer therapy[J]. Trends in Cancer, 2017, 611-614.
Authors:
Mahadevappa, R.
;
Ma, R.
;
Kwok, H. F.
Favorite
|
|
Submit date:2022/06/02
Venom Peptides
Targeted Cancer Therapy
Immunotherapy
Combinatorial Anticancer Drugs
Enhancement of the bioavailability of a novel anticancer compound (acetyltanshinone IIA) by encapsulation within mPEG-PLGA nanoparticles: A study of formulation optimization, toxicity, and pharmacokinetics
Journal article
Wang, Qi, Wei, Na, Liu, Xiaofeng, Chang, Alex, Luo, Kathy Qian. Enhancement of the bioavailability of a novel anticancer compound (acetyltanshinone IIA) by encapsulation within mPEG-PLGA nanoparticles: A study of formulation optimization, toxicity, and pharmacokinetics[J]. Oncotarget, 2017, 8(7), 12013-12030.
Authors:
Wang, Qi
;
Wei, Na
;
Liu, Xiaofeng
;
Chang, Alex
;
Luo, Kathy Qian
Favorite
|
TC[WOS]:
12
TC[Scopus]:
12
|
Submit date:2018/12/18
Acetyltanshinone Iia
Anticancer Drugs
Bioavailability
Mpeg-plga
Pharmacokinetics
Toxicity
FOXO Signaling Pathways as Therapeutic Targets in Cancer
Journal article
Farhan, Mohd, Wang, Haitao, Gaur, Uma, Little, Peter J., Xu, Jiangping, Zheng, Wenhua. FOXO Signaling Pathways as Therapeutic Targets in Cancer[J]. INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2017, 13(7), 815-827.
Authors:
Farhan, Mohd
;
Wang, Haitao
;
Gaur, Uma
;
Little, Peter J.
;
Xu, Jiangping
; et al.
Favorite
|
TC[WOS]:
330
TC[Scopus]:
341
IF:
8.2
/
8.3
|
Submit date:2018/10/30
Apoptosis
Nuclear Translocation
Foxo
Cell Proliferation
Anticancer Drugs
Transcription Factors
B-TYPE NATRIURETIC PEPTIDES
Book chapter
出自: Venomous Reptiles and Their Toxins, UK:Oxford University Press, 2015, 页码:312-317
Authors:
Fry, B. G.
;
Roelants, K.
;
Jackson, N. W.
;
Sunagar, K.
;
Takacs, Z.
; et al.
Favorite
|
|
Submit date:2022/06/02
Natriuretic peptides
lizard Venoms
Helokinestatins
anticancer drugs